Telix Pharmaceuticals (ASX: TLX) has completed the submission of a Biologics License Application (BLA) to the UD FDA for its investigational radiodiagnostic PET agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).
The rolling BLA submission, initiated in December 2023, with timelines pre-agreed with the FDA, was based on Telix’s successful global Phase III ZIRCON study in ccRCC.
The clear cell variant of renal cancer is the most common and aggressive sub-type of kidney cancer. The ZIRCON study met all co-primary and secondary endpoints, demonstrating a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in small, difficult to detect lesions.
As part of the BLA submission process, Telix has requested a Priority Review under the eligibility criteria of the Breakthrough Therapy designation. If granted, this would potentially support an expedited review time. If Zircaix is approved, TLX250-CDx will be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer to be commercially available in the US and further builds on Telix’s successful urology imaging franchise.
“Completing the BLA submission for TLX250-CDx represents a significant milestone for Telix as we bring our Breakthrough investigational kidney cancer imaging agent closer to market as a non-invasive diagnostic for patients,” Chief Development Officer, James Stonecypher, said.
“We believe TLX250-CDx is a natural follow-on product to Illuccix as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix.”
